GoAI
Get started
Voyager Therapeutics, Inc. logo

Voyager Therapeutics, Inc.

VYGR

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.39

+$0.07 · +2.11%

Aug 21, 4:00 PM ET

VYGR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

47

Fair Value

Momentum

34

Weakening

Sentiment

44

Mixed

Risk resilience

38

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Alfred W. Sandrock Jr.
Listed since
Nov 11, 2015
Employees
141

Market position

Day range

Current $3.39

52-week range

Current $3.39

Open
$3.33
Previous close
$3.32
Volume
424.44K
0.72× average
Average volume
590K
Average daily volume
Market cap
204.83M USD
Beta
1.31
Market reference 1
50-day average
$3.3466
+1.30% above average
200-day average
$3.8111
-11.05% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
201.86M USD
P/E (TTM)
-1.87×
P/B (TTM)
1.33×
P/S (TTM)
5.94×
EV / EBITDA
-1.75×
Earnings yield
-51.90%
Free cash flow yield
-58.56%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-104.16%
Operating margin
-340.08%
Net margin
-312.63%
Return on equity
-61.06%
Return on assets
-47.46%
Return on invested capital
-56.44%

Financial health

Debt / equity
0.21×
Current ratio
7.64×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends143%-28%-199%-369%Gross margin, FY2021: -97.21%Gross margin, FY2022: -36.32%Gross margin, FY2023: 63.13%Gross margin, FY2024: 100.00%Gross margin, FY2025: -227.62%Operating margin, FY2021: -196.76%Operating margin, FY2022: -124.27%Operating margin, FY2023: 48.80%Operating margin, FY2024: -104.11%Operating margin, FY2025: -326.56%Net margin, FY2021: -190.29%Net margin, FY2022: -113.45%Net margin, FY2023: 52.93%Net margin, FY2024: -81.25%Net margin, FY2025: -296.53%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -97.21%. Gross margin FY2022 -36.32%. Gross margin FY2023 63.13%. Gross margin FY2024 100.00%. Gross margin FY2025 -227.62%. Operating margin FY2021 -196.76%. Operating margin FY2022 -124.27%. Operating margin FY2023 48.80%. Operating margin FY2024 -104.11%. Operating margin FY2025 -326.56%. Net margin FY2021 -190.29%. Net margin FY2022 -113.45%. Net margin FY2023 52.93%. Net margin FY2024 -81.25%. Net margin FY2025 -296.53%.

Income trends

Revenue

40.37M USD-49.53%

Operating income

−131.84M USD-58.30%

Net income

−119.72M USD-84.18%
Income trends across reported periods288.19M USD135.45M USD−17.29M USD−170.03M USDRevenue, FY2021: 37.42M USDRevenue, FY2022: 40.91M USDRevenue, FY2023: 250.01M USDRevenue, FY2024: 80M USDRevenue, FY2025: 40.37M USDOperating income, FY2021: −73.62M USDOperating income, FY2022: −50.84M USDOperating income, FY2023: 122.01M USDOperating income, FY2024: −83.29M USDOperating income, FY2025: −131.84M USDNet income, FY2021: −71.2M USDNet income, FY2022: −46.41M USDNet income, FY2023: 132.33M USDNet income, FY2024: −65M USDNet income, FY2025: −119.72M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 37.42M USD. Revenue FY2022 40.91M USD. Revenue FY2023 250.01M USD. Revenue FY2024 80M USD. Revenue FY2025 40.37M USD. Operating income FY2021 −73.62M USD. Operating income FY2022 −50.84M USD. Operating income FY2023 122.01M USD. Operating income FY2024 −83.29M USD. Operating income FY2025 −131.84M USD. Net income FY2021 −71.2M USD. Net income FY2022 −46.41M USD. Net income FY2023 132.33M USD. Net income FY2024 −65M USD. Net income FY2025 −119.72M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue40.37M USD80M USD250.01M USD40.91M USD37.42M USD
Cost of goods sold132.27M USD—92.17M USD55.76M USD73.79M USD
Gross profit−91.9M USD80M USD157.84M USD−14.86M USD−36.37M USD
Research and development134.67M USD127.37M USD92.17M USD60.76M USD73.79M USD
Selling, general, and administrative36.44M USD35.92M USD35.82M USD30.98M USD37.25M USD
Operating expenses39.94M USD163.29M USD35.82M USD35.98M USD37.25M USD
Interest income10.62M USD18.33M USD11.72M USD1.79M USD—
Depreciation and amortization4.06M USD4.73M USD4.44M USD6.19M USD5.17M USD
Operating income−131.84M USD−83.29M USD122.01M USD−50.84M USD−73.62M USD
Net income−119.72M USD−65M USD132.33M USD−46.41M USD−71.2M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+56.39%
11 comparable reports
Latest EPS result
-0.4
Estimate -0.48 · Beat by 17.32%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.31-0.42-0.52-0.63Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual -0.59, estimate -0.35, surprise -68.57%, Miss. Q2 2025, reported May 6, 2025: actual -0.53, estimate -0.35, surprise -51.43%, Miss. Q3 2025, reported Aug 6, 2025: actual -0.57, estimate -0.48, surprise -18.75%, Miss. Q4 2025, reported Nov 10, 2025: actual -0.47, estimate -0.53, surprise +11.32%, Beat. Q1 2026, reported Mar 9, 2026: actual -0.46, estimate -0.54, surprise +14.81%, Beat. Q2 2026, reported May 7, 2026: actual -0.47, estimate -0.54, surprise +12.96%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.4, estimate -0.484, surprise +17.32%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.41, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates16.36M11.64M6.92M2.2MQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual 6.28M USD, estimate 12.95M USD, surprise -51.51%, Miss. Q2 2025, reported May 6, 2025: actual 6.47M USD, estimate 13.91M USD, surprise -53.45%, Miss. Q3 2025, reported Aug 6, 2025: actual 5.2M USD, estimate 7.86M USD, surprise -33.83%, Miss. Q4 2025, reported Nov 10, 2025: actual 13.37M USD, estimate 10.49M USD, surprise +27.38%, Beat. Q1 2026, reported Mar 9, 2026: actual 15.34M USD, estimate 10.49M USD, surprise +46.17%, Beat. Q2 2026, reported May 7, 2026: actual 2.59M USD, estimate 8.79M USD, surprise -70.49%, Miss. Q3 2026, reported Aug 6, 2026: actual 3.17M USD, estimate 4.52M USD, surprise -29.97%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate 6.35M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

21 ratings
Strong buy00%
Buy1781%
Hold419%
Sell00%
Strong sell00%

VYGR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding VYGR

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
5.07M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
4.5M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.86M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
1.62M
Weight
0.01%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
1.22M
Weight
0.01%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
898.56K
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
594.16K
Weight
0.04%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
522.7K
Weight
0.01%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%

Continue in GoAI

Research VYGR

research.disclaimer